Resources

AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.

To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database

Results

showing 1-10 of 300

Moving a Product to the “Real World”

A visual roadmap illustrating the key stages transitioning a product from clinical trials to large-scale real-world implementation.

Prevention Option:

November 2024


Dapivirine Vaginal Ring Regulatory Approval

Regulatory approvals, pending decisions, and appeals as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.

Prevention Option:

November 2024


Cabotegravir Regulatory Approval

Regulatory approvals and those pending for cabotegravir as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.

Prevention Option:

November 2024


Dapivirine Vaginal Ring Volume

DVR supply available to low- and middle-income countries as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.

Prevention Option:

November 2024


Cabotegravir Volume

Allocation of non-commercial cabotegravir for PrEP supply in low- and middle-income countries, 2023-2026, as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on...

Prevention Option:

November 2024


Dapivirine Vaginal Ring Implementation

Ongoing and planned implementation studies for the dapivirine vaginal ring as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.

Prevention Option:

November 2024


Cabotegravir Implementation

Implementation studies completed, ongoing, or planned for cabotegravir as of October 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.

Prevention Option:

November 2024


PrEP Price Comparison

Comparing the annual price of oral TDF/FTC vs. the dapivirine vaginal ring and injectable cabotegravir. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.

Prevention Option:

November 2024


PrEP Approval Status in Latin America, 2024

Since 2019, rates of HIV acquisition in Latin America have been trending upward, from 110,000 annually in 2019 to approximately 120,000 in 2023. At the same time, Latin America has taken strides to combat this trend, from increasing PrEP initiation...

Prevention Option:

October 2024


PrEP Initiations in Latin America, 2019-2024

Latin American countries account for 306,000 cumulative PrEP initiations in the Global PrEP Tracker as of Q2 2024, which represent 4% of the global total. Since 2019, PrEP initiations across the region continue to increase at a steady rate, with...

Prevention Option:

October 2024


showing 1-10 of 300